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ABSTRACT: Despite the astonishing breadth of enzymes
in nature, no enzymes are known for many of the valuable
catalytic transformations discovered by chemists. Recent
work in enzyme design and evolution, however, gives us
good reason to think that this will change. We describe a
chemomimetic biocatalysis approach that draws from
small-molecule catalysis and synthetic chemistry, enzymol-
ogy, and molecular evolution to discover or create
enzymes with non-natural reactivities. We illustrate how
cofactor-dependent enzymes can be exploited to promote
reactions ﬁrst established with related chemical catalysts.
The cofactors can be biological, or they can be non-
biological to further expand catalytic possibilities. The
ability of enzymes to amplify and precisely control the
reactivity of their cofactors together with the ability to
optimize non-natural reactivity by directed evolution
promises to yield exceptional catalysts for challenging
transformations that have no biological counterparts.
■ INTRODUCTION
Challenges in catalysis demand the creation of enzymes with
activities not yet found in the biological world. Nature has
evolved a certain set of synthetic strategies and uses an
impressive array of enzyme catalysts to construct everything
from simple metabolites to complex natural products. For the
production of medicinal compounds, fuels, materials, or
chemicals,1 however, nature’s synthetic strategies may not be
ideal or even appropriate. Toward this end, one might desire
enzymes that act on nonbiological functional groups or
promote non-natural bond constructions while still capitalizing
on enzymes’ extraordinary powers of rate acceleration and
selectivity. Developing genetically encoded catalysts for non-
natural chemical transformations will expand the reach of
biocatalysis and facilitate construction of biocatalytic routes for
the synthesis of valuable chemical products in vitro and in vivo.2
Enzymes constructed only of the 20 canonical amino acids
catalyze a remarkable range of chemistries. To achieve certain
types of activity, however, proteins are often augmented with
organic metabolites or metal ions known as cofactors; these
species have functional groups and properties that enable the
protein−cofactor complex to catalyze reactions that the protein
alone cannot.3 In turn, the protein sequence plays a critical role
in controlling and amplifying the reactivity of the cofactor,
enabling the ensemble to eﬀect transformations that the
cofactor often cannot perform alone or dictating the regio-,
diastereo-, or enantioselectivity of those transformations.
Furthermore, a given cofactor can often catalyze a multitude
of chemically diverse transformations, and the protein structure
acts to guide reactivity down one out of many possible
pathways.
Many cofactor-dependent enzymes have been studied in
depth with regard to their reaction mechanisms and the
complex interactions between protein and cofactor that
promote catalysis. The enzymologists carrying out these studies
almost always focus on the natural function and substrate(s). At
the same time, synthetic chemists have developed catalysts for a
broad range of reactions that are completely absent in biology,
either because nature has not found it advantageous to use
them or because they require reagents not normally found in
biology. In many cases, the small-molecule catalysts resemble
natural cofactors; sometimes their creation was inspired by
enzymes, in a biomimetic chemistry approach to catalyst
design.4 Similarities between many chemical catalysts and
natural cofactors, both structural and functional, raise the
possibility that the non-natural activities of small-molecule
catalysts can be translated back into the corresponding
cofactor-dependent enzymes. As proteins can provide exquisite
control over reaction pathways, this chemomimetic biology
strategy can improve on the eﬃciencies and selectivities of
small-molecule catalysts just as natural enzymes improve on the
activities and selectivities of their cofactors (Figure 1).
This Perspective will demonstrate how a chemomimetic
approach can generate new biocatalysts from existing cofactor-
dependent enzymes. Other approaches, including catalytic
antibodies5 and de novo designed enzymes,6 have also delivered
biocatalysts that catalyze reactions not known in nature.
However, despite extensive eﬀorts, their reactions have been
limited to a relatively narrow set of transformations, and most
of the new enzymes do not catalyze reactions at useful rates. In
contrast, by repurposing existing cofactor-dependent enzymes
for new chemistry, protein engineers and chemists have created
enzymes that execute a diverse range of synthetically
challenging nonbiological reactions. Cofactors enable the
generation of unique reactive intermediates in enzyme active
sites, whereas synthetic chemistry serves as a guide for the types
of activity that can be achieved with a given reactive motif, even
if they have not been observed in nature. This Perspective is
not intended as an extensive review of the literature but, rather,
a discussion of case studies that illustrate how new activities
may be introduced into existing enzymes. We will discuss novel
activities for enzymes that use thiamine and heme cofactors as
well as proteins that use natural amino acids for non-native
aminocatalysis.7 We will also brieﬂy consider the introduction
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of artiﬁcial cofactors into proteins to create new enzymes.
Throughout, we will focus on reactions that are not biological
rather than on creating new catalysts for transformations that
are already known in nature, for which there is ample
precedent.8
Interest in engineering non-natural enzyme activity is
growing rapidly. Apart from better understanding of enzyme
structures and mechanisms, one key driving force has been
ready access to powerful methods of protein engineering. As
natural enzymes are rarely proﬁcient at performing non-natural
chemistries, optimization of the protein structure is required to
access synthetically useful catalysts; this is now possible and is
in fact relatively straightforward. A hallmark of enzymes is that
they can evolve and adapt under selective pressure, and this
evolvability can be exploited in the laboratory to optimize
enzymes via an iterative process of mutagenesis and screening
for a desired outcome. This engineering approach, known as
directed evolution, enables rapid tuning of key catalyst features
such as selectivity, activity, and stability and circumvents our
still poor understanding of how sequence aﬀects enzyme
function.9 Thus, once a small amount of activity for a given
transformation is discovered, the activity can often be greatly
improved by introducing one or a few mutations at a time.
Although mutagenesis guided by mechanistic understanding
can sometimes be a successful approach to improving enzyme
activities, the creation of exceptional catalysts almost always
relies (at least in part) on a wider exploration of protein
sequence space. In the realm of cofactor-dependent enzymes,
the manner in which protein structure impacts the inherent
reactivity of the cofactor provides fertile ground for protein
engineers to alter the course of chemistry just by mutation of
the protein sequence. In the world of chemical catalysis, there is
no general strategy equivalent to evolution for optimizing
catalyst structure. Catalyst modiﬁcation often requires laborious
resynthesis (as opposed to relatively straightforward gene
modiﬁcation), and subtle beneﬁcial structural mutations rarely
accumulate over generations of small-molecule catalyst
optimization.
The creation of enzymes for nonbiological processes is an
emerging ﬁeld full of promise at the interface between
chemistry and biology. Opportunities abound for protein
engineers to exploit the wealth of knowledge gained from
mechanistic enzymology and synthetic chemistry. Our goal here
is to introduce concepts in this ﬁeld and point to some of the
opportunities; we encourage chemists to look at enzymes in a
new way and contribute their intuition and insights to creating
enzymes with new, synthetically useful activities.
■ THIAMINE-DEPENDENT ENZYMES
Chemists and protein engineers have developed new reactions
using enzymes dependent on thiamine diphosphate (ThDP) by
taking advantage of the unusual catalytic mechanisms enabled
by this cofactor. Thiamine diphosphate comprises an N-alkyl
thiazolium core, a tethered pyrimidine ring, and a diphosphate-
terminated side chain (Scheme 1). The thiamine cofactor is
noncovalently bound to the enzyme, with the diphosphate
group binding a second metal cofactor (typically, magnesium).
Enzymes containing ThDP possess the unique ability to forge
or break C−C bonds between two oxidized carbon centers;
these enzymes catalyze decarboxylations (as in pyruvate
decarboxylase), carboligations (as in transketolases), and
oxidative transformations (as in pyruvate dehydrogenase).10
Pyruvate decarboxylase (PDC), a particularly well-studied
thiamine-dependent enzyme, catalyzes the conversion of
pyruvate to acetaldehyde and carbon dioxide (Scheme 1).
Early studies demonstrated that ThDP can perform certain
functions of thiamine-dependent enzymes, indicating that the
cofactor itself contains all of the functionality required for
catalysis.11 It was not until 1957, however, that the now-
accepted mechanism of thiamine catalysis was put forward by
Breslow, who provided evidence for a mechanism involving
deprotonation of the thiazolium ring at C2 (pKa ≈ 18)
12 to give
the thiazolium ylide 1 (Scheme 2).13 A resonance form of this
ylide is the nucleophilic carbene 2, in which a carbon atom
bearing a sextet of electrons is stabilized by σ-electron
withdrawal and π-electron donation from the adjacent
heteroatoms. In the mechanism of pyruvate decarboxylation
by PDC, addition of the nucleophilic carbene carbon (C2) to
the pyruvate keto-group gives the covalent adduct 3. The
electron-withdrawing nature of the thiazolium ring then
facilitates decarboxylation to yield the enaminol moiety 4,
known as the Breslow intermediate. This species is strongly
nucleophilic; it may undergo protonation to provide thiazolium
Figure 1. Chemomimetic strategies guide the creation of biocatalysts
for reactions not known in nature.
Scheme 1. Thiamine Diphosphate and the Native Activity of
Thiamine-Dependent Pyruvate Decarboxylase (PDC)10
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5, which then collapses to release the product acetaldehyde and
regenerate the active carbene form of the cofactor.
Whereas the cofactor alone decarboxylates pyruvate, the
protein dramatically accelerates catalysis: by up to a factor of
1012 for yeast PDC.14 Various mechanisms have been
implicated in this rate acceleration. Conserved polar
interactions with the pyrimidine ring (provided by E51 and
G413 in PDC) increase the basicity of the 4′-nitrogen, whereas
a conserved hydrophobic residue (I415 in yeast PDC) acts as a
fulcrum between the two heteroaromatic rings, enforcing a V-
shaped conformation of the cofactor and positioning the 4′-
nitrogen in a favorable orientation to perform an intramolecular
deprotonation of C2 (Scheme 2).15 These active site features
eﬀectively lower the pKa at C2 and accelerate deprotonation of
the thiazolium.16 Next, upon formation of the covalent adduct
3, studies on other ThDP-dependent enzymes suggest that the
protein promotes decarboxylation by enforcing maximal orbital
overlap between the scissile C−C bond and the thiazolium π-
system in the decarboxylation transition state.17 Finally, speciﬁc
residues have been implicated in both protonation of the
Breslow intermediate and deprotonation of the alcoholic
proton in the acetaldehyde-forming step.10 The protein
sequence of PDC thus functions to accelerate many steps
throughout the catalytic cycle.
Concurrent with the enzymology studies delineating the
mode of action of ThDP-dependent enzymes, chemists
examining small molecules related to thiamine found that a
broad range of heterocyclic structures (such as those shown in
Scheme 3) undergo deprotonation to yield nucleophilic
carbenes analogous to intermediate 2. These species, termed
N-heterocyclic carbenes (NHCs), have found broad application
in catalysis; similar to the mechanism of thiamine catalysis,
these carbenes condense with carbonyl compounds to give
Breslow intermediates.19 This activation mode is particularly
useful, as it reverses the typical reactivity of a carbonyl group:
carbonyl carbon atoms are typically electrophilic, but formation
of the Breslow intermediate (an acyl anion equivalent) renders
the carbonyl carbon nucleophilic, enabling unique bond
constructions. Using this catalytic manifold, chemists have
accomplished many reactions that are not known to be
catalyzed by thiamine-dependent enzymes in nature; these
include benzoin and aza-benzoin condensations as well as
Stetter, hydroacylation, and various annulation reactions.19 Of
the various catalyst systems that have been developed,
triazolium-derived N-heterocyclic carbenes have been found
to be especially useful for achieving enantioselective trans-
formations.20
Recognizing the similarities between enzyme and NHC
catalysts, biochemists and protein engineers have sought to use
thiamine-dependent enzymes to perform some of these
nonbiological synthetic transformations.21 Many ThDP-de-
pendent enzymes have been found to promote benzoin-type
condensations between two aldehydes; in the catalytic
mechanism, generation of the Breslow intermediate 6 is
achieved via α-deprotonation of the initial covalent adduct
rather than α-decarboxylation, as in the mechanism of PDC
(Scheme 4A).22 Nucleophilic addition to a second equivalent of
aldehyde followed by expulsion of thiamine then gives the α-
hydroxyketone 7. Various other enzymatic heterocouplings
between aromatic and aliphatic aldehydes have also been
established.23
Particularly notable applications of ThDP-dependent en-
zymes have been found for reactions that have historically
proven to be challenging for their small-molecule equivalents.
In one such transformation, the asymmetric cross-benzoin
reaction, one aldehyde must exclusively react with the carbene
while a second (chemically very similar) aldehyde must
function only as an acceptor. Due to this chemoselectivity
problem, small-molecule methods are typically limited to
aldehyde homocoupling. Müller and co-workers identiﬁed
two thiamine-dependent enzymes, benzaldehyde lyase (BAL)
from Pseudomonas ﬂuorescens and a variant of benzoylformate
decarboxylase (BFD) from Pseudomonas putida, that success-
fully execute the reaction.24 Several aldehydes bearing ortho-
substituents (such as 2-chlorobenzaldehyde, 8) were selected as
Scheme 2. Mechanism of Thiamine Catalysis in Pyruvate
Decarboxylase and Active Site Architecture of Pyruvate
Decarboxylase from Saccharomyces cerevisiae10,a
aThDP is shown in gray, active site residues are in yellow, and
magnesium is in green; PDB: 1PVD.18
Scheme 3. Small-Molecule Thiamine Equivalents (N-
Heterocyclic Carbene Precursors) Used To Catalyze Diverse
Organic Transformations19
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acceptor substrates because they do not undergo enzyme-
catalyzed homocoupling, suggesting that their condensation
with the thiamine cofactor is not possible. Thus, for the
example shown in Scheme 4, only benzaldehyde 9 reacts with
the carbene to give the Breslow intermediate 10; subsequent
addition to the favored acceptor 8 yields the cross-benzoin
adduct with high chemo- and enantioselectivity. Using 2-
chlorobenzaldehyde as the acceptor, selective cross-benzoin
couplings may be achieved with a range of electronically diverse
donor aldehydes.
Directed evolution of thiamine-dependent enzymes has been
performed, enabled by a colorimetric high-throughput screen
for the detection of α-hydroxyketone products. These eﬀorts
have enhanced the activities and enantioselectivities, as well as
expanded the substrate scope, of enzymes performing benzoin-
type condensations.25
Instead of adding to carbonyls in a 1,2-fashion, the Breslow
intermediate may also add in a 1,4-conjugate fashion to α,β-
unsaturated carbonyl compounds; the resulting transformation
is known as the Stetter reaction. Some of the earliest reported
Stetter reactions were actually achieved using thiazolium 11,
which features the core of the thiamine cofactor (Scheme 5).26
However, achieving intermolecular, enantioselective Stetter
reactions has been very challenging for small-molecule NHC
catalysts; although examples of this activity have been
developed, signiﬁcant limitations remain with regard to scope
and enantioselectivity.27 Dresen et al. demonstrated that the
thiamine-dependent enzyme PigD from Serratia marcescens
performs the intermolecular Stetter coupling of an acetaldehyde
unit (derived from pyruvate) with enones (Scheme 5).28 This
enzyme was postulated to perform a Stetter reaction as its
native function in the biosynthesis of prodigiosin,29 but
experiments conducted with puriﬁed PigD and the proposed
enal substrates for such reactions provided only the products of
1,2-addition. Upon evaluation of enone substrates, however,
Stetter activity was observed and no 1,2-addition could be
detected. A variety of enones having aliphatic, aromatic, and
heteroaromatic functionalities at the 4-position undergo the
PigD-catalyzed Stetter reaction, in many cases with excellent
enantioselectivity.30 Subsequent studies identiﬁed two PigD
homologues that also display “Stetterase” activity.31
Benzaldehyde lyase (BAL) has also been engineered to
perform the formose reaction, in which dihydroxyacetone is
produced from the condensation of three equivalents of
formaldehyde. Whereas chemical catalysts, including thiazolium
salts, are known to perform this transformation, the reaction is
not known in biology. Siegel et al. used computational design
and directed evolution to identify a variant having seven
mutations and 100-fold improved “formolase” activity relative
to that of BAL.32 This variant was used in a biosynthetic
pathway for the conversion of formate into three-carbon
metabolites.
In all of these examples, a mechanistic understanding of
thiamine catalysis combined with experience from the synthetic
chemistry of small-molecule thiamine analogues guided the
discovery of new enzyme activities. By mimicking reactions ﬁrst
achieved with chemical catalysts related to the thiamine
cofactor, native enzymes could be used to perform desired
non-natural functions and, notably, even provide solutions to
long-standing synthetic challenges. These activities proceed via
the same key intermediate (the Breslow intermediate) as that in
the natural enzyme transformations, but they access or utilize
the intermediate in a nonbiological manner via selection of
appropriate chemical reagents.
■ HEME-DEPENDENT ENZYMES
Heme-containing enzymes have been useful starting points for
new enzyme activities. Particularly versatile are the cytochrome
P450s (CYPs), a remarkable class of iron porphyrin-dependent
enzymes that participate in xenobiotic metabolism and natural
product biosynthesis.33 These enzymes activate dioxygen, in a
process requiring two electrons from NAD(P)H, to perform a
multitude of oxygenation reactions including C−H hydrox-
ylation, epoxidation, sulfoxidation, and heteroatom deal-
kylation. The mechanism of P450-catalyzed hydroxylation
proceeds via a series of distinct iron intermediates to achieve
Scheme 4. Benzoin (A) and Cross-Benzoin (B) Reactions
Promoted by Thiamine-Dependent Benzoylformate
Decarboxylase (BFD)22−24
Scheme 5. Thiamine-Dependent Enzyme PigD Performs the
Intermolecular Stetter Reaction28
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the insertion of an atom from dioxygen into a C−H bond.34
First, substrate binding displaces a water ligand of the resting
ferric state of the cofactor, giving the penta-coordinate
intermediate 12 (Scheme 6). This event induces a transition
of the heme iron from low to high spin, increasing its reduction
potential (by 140 mV for P450BM3)
35 and triggering electron
transfer from a reductase partner. Upon reduction of the
cofactor to its ferrous state (13), molecular oxygen binds to
give a ferric−superoxide complex 14; a subsequent second
electron transfer followed by protonation then delivers the
iron−hydroperoxy species 15. This species, termed Compound
0, is protonated to release water and form a key iron(IV)−oxo
porphyrin radical cation intermediate termed Compound I.
This intermediate is the species that performs most of the
oxygenation chemistry characteristic of P450s; in hydroxylation,
Compound I abstracts a hydrogen atom from the substrate to
generate an organic radical as well as the iron(IV)−hydroxyl
species, Compound II. Radical rebound delivers the oxygenated
product and returns the cofactor to its ferric resting state.
Protein engineers have targeted a range of P450s for
applications in biocatalysis, but one of the most widely used
is P450BM3 from Bacillus megaterium (CYP102A1). This soluble
protein contains heme and diﬂavin reductase domains fused in
a single polypeptide chain and naturally performs the
subterminal hydroxylation of long chain fatty acids.36
Although all of the catalytic intermediates in the cytochrome
P450 monooxygenation cycle are heme-bound, the protein’s
primary sequence makes critical contributions to catalysis. In all
P450s, the heme iron is ligated by an axial cysteine thiolate
residue (C400 in P450BM3). Coordination by an electron-rich
ligand decreases the reduction potential of the cofactor,
preventing initiation of the catalytic cycle in the absence of
substrate. The thiolate ligand is also postulated to promote
heterolytic cleavage of the O−O bond in the iron−hydroperoxy
intermediate 15.34 Furthermore, as demonstrated by recent
studies,37 thiolate ligation increases the basicity (pKa) of
Compound II, causing Compound I to favor abstraction of a
hydrogen atom from the substrate over single-electron
oxidation events that would be destructive to the protein.
Another highly conserved residue is an active-site threonine
(T268 in P450BM3) that has been implicated in protonation and
stabilization of heme-bound intermediates through active-site
water molecules.38 Protonation of the iron−hydroperoxy
intermediate 15 mediated by this threonine likely promotes
heterolytic O−O bond scission in the generation of Compound
I.
Synthetic chemists have long sought to replicate the
remarkable reactivity of cytochrome P450s, and many small
molecules have been developed that mimic their oxene transfer
activity; some of these catalysts are metalloporphyrin
complexes structurally analogous to the native heme cofactor.40
At the same time, many metalloporphyrins perform reactions
unknown in biology; prominent among these is the transfer of
carbenes and nitrenes to organic substrates.41 In such reactions,
an activated chemical precursor such as a diazo or azido species
reacts with a transition metal (typically, Ru, Rh, Cu, Fe, Co, or
Mn) to give a metal carbenoid or metal nitrenoid, respectively
(Scheme 7). These electrophilic species, electronically analo-
gous to the iron(IV)−oxo intermediate Compound I, may
subsequently transfer the carbene or nitrene to an organic
substrate. This mechanism has been employed to achieve a
number of challenging non-natural transformations including
cyclopropanation, C−H alkylation, and C−H amination.42
Whereas porphyrin complexes are often highly active toward
many of these reactions, they are typically not highly
enantioselective. Instead, a number of nonporphyrin chiral
scaﬀolds, such as copper bis(oxazolines) and dirhodium
carboxylates or carboxamidates, have been more broadly useful
for asymmetric catalysis (Scheme 7).
Several years ago, our group demonstrated that cytochrome
P450BM3 can, in fact, perform the cyclopropanation of styrenes
via nonbiological metal carbenoid intermediates.43 In this mode
of catalysis, sodium dithionite (Na2S2O4) ﬁrst converts the
resting ferric state of P450BM3 to an active ferrous state
(Scheme 8). Reaction with the reagent ethyl diazoacetate
(EDA, 16) then yields the iron carbenoid 17 with concomitant
Scheme 6. Mechanism of Monooxygenation Catalyzed by
Cytochrome P450s and Active Site Structure of Cytochrome
P450BM3 Bound to N-Palmitoylglycine
34,a
aThe heme is shown in gray, N-palmitoylglycine is in green, active site
residues are in yellow, and iron is in orange; PDB: 1JPZ.39
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loss of dinitrogen. The electrophilic carbenoid intermediate
reacts with styrene (18) to provide the cyclopropane product
19; this carbene transfer step returns the cofactor to the
catalytically active ferrous state. Wild-type P450BM3 performs
the cyclopropanation of styrene with very low eﬃciency (5 total
turnovers) and with low levels of diastereo- and enantiose-
lectivity (37:63 cis/trans and 27% ee for the cis-cyclopropane).
However, mutating the highly conserved threonine 268 to
alanine is strongly activating, providing an enzyme with over
60-fold improved cyclopropanation activity as well as excellent
selectivity for a single enantiomer of the trans-cyclopropane
(Scheme 8). Other variants were identiﬁed that preferentially
deliver the cis isomer; the variant P450BM3-CIS T438S contains
14 mutations relative to wild-type P450BM3 and produces the
cis-cyclopropane with excellent diastereo- and enantioselectiv-
ity. Thus, the inherent reactivity of the heme cofactor allows
new reactions to be performed with a P450 enzyme, whereas
changes to the protein sequence both enhance the activity and
allow for exquisite control over the outcome of the new
pathway.
Whereas axial ligation of the iron center by a cysteine residue
is critical to the monooxygenation activity of cytochrome
P450s, we found that mutation of the axial cysteine in P450BM3
to serine (C400S), histidine, and even other amino acids is
activating toward carbene transfer and enables catalysis in
whole cells.44−47 For cysteine-ligated P450s, a strong reductant
such as dithionite (E°′ = −660 mV vs the standard hydrogen
electrode, SHE) is required to convert the resting ferric state to
the ferrous state (E°′ FeIII/II = −420 mV vs SHE for wild-type
P450BM3) in the absence of a substrate-induced spin shift.
Mutation of the axial cysteine to serine, however, signiﬁcantly
increases the reduction potential of the ferric state (to E°′
FeIII/II = −293 mV vs SHE).44 The C400S and other mutations
enable the cyclopropanation of styrene in whole cells, where
the endogenous reductant NADPH (E°′ = −320 mV vs SHE)
is capable of performing the required initial electron transfer. As
the Soret peak of the ferrous CO-bound enzyme is shifted from
450 to 411 nm in the serine-ligated variants, we termed these
catalysts “cytochrome P411s”. Furthermore, crystal structures
show that the serine residue coordinates the iron center and
does not cause signiﬁcant structural changes to the protein.44,48
Variant P411BM3-CIS catalyzes the cyclopropanation of styrene
with very high selectivity in whole cells and is capable of greater
than 67 000 turnovers (Scheme 8). In addition, the C400S
mutation abolishes the monooxygenation activity; this single
mutation thus enhances a non-natural function at the expense
of the native function. Mutation of the axial residue tunes the
electronics of the iron center, adapting the enzyme to the
demands of the non-native catalytic cycle. Other cytochrome
P450s and other heme-containing proteins also catalyze
cyclopropanation.43,45
Histidine-ligated cytochrome P450BM3 mutants were eval-
uated toward the cyclopropanation of acrylamide 20 as the key
step in a formal synthesis of the antidepressant levomilnacipran
(Scheme 9).46 P450BM3 T268A C400H performs the carbene
transfer reaction with good activity and selectivity for the
desired diastereomer, but it does so with only moderate
enantioselectivity. Directed evolution was performed by
evaluating site-saturation libraries at active site residues for
improvements in enantiomeric excess and accumulating the
beneﬁcial mutations. The catalyst identiﬁed by this approach,
termed BM3-Hstar, contains an additional three mutations and
provides the cyclopropane 21 with excellent selectivity. BM3-
Scheme 7. Transition Metal Complexes Perform Catalysis
via the Formation of Metal Carbenoid and Nitrenoid
Intermediates41,42
Scheme 8. Variants of Cytochrome P450BM3 Catalyze the
Cyclopropanation of Styrenes via Carbene Transfer43,44
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Hstar is also highly active, performing cyclopropanation with an
initial rate of over 1000 turnovers per minute, and even
maintains activity under aerobic conditions. It is notable that
P450BM3 tolerates the introduction of the large histidine side
chain at the axial position; the crystal structure of a variant of
the thermostable CYP119 from Sulfolobus acidocaldarius having
the corresponding axial Cys-to-His mutation reveals dramatic
structural rearrangements caused by non-native ligation.49
Fasan’s group recently demonstrated that myoglobin (Mb), a
heme-containing protein that naturally features an axial
histidine ligand, also performs cyclopropanation eﬃciently via
carbene transfer when a second, distal histidine is replaced with
a smaller side chain.50 Under reducing, anaerobic conditions,
sperm whale Mb catalyzes the cyclopropanation of styrene with
EDA with good diastereoselectivity for the trans isomer but
minimal enantioselectivity (6% ee). However, introduction of
mutations at H64 and V68, both located on the distal face of
the heme, created a highly diastereo- and enantioselective
catalyst capable of greater than 46 000 turnovers at high
substrate concentrations (Scheme 9). The Mb variant is active
toward cyclopropanation of a range of terminal styrenes.
Finally, our group has shown that variants of P450BM3 perform
the N-alkylation of anilines via formal metal carbenoid insertion
into N−H bonds,52 and Fasan has described Mb-promoted N−
H insertion53 and S−H insertion reactions (Scheme 10).54
Given that cytochrome P450s (and other heme proteins)
readily adopt the ability to perform carbene transfer, one might
anticipate that they could also display nitrene transfer activity.
Indeed, in an early report, Dawson and Breslow showed that
incubating rabbit liver microsomal P450s with iminoiodinanes
yielded the products of nitrogen insertion into C−H bonds,
presumably via a metal nitrenoid intermediate, with very low
activity (2 turnovers).55 We were inspired by this report to
investigate sulfonylazides as nitrene precursors for catalysis with
cytochrome P450BM3.
56 Analogous to the mechanism of
carbene formation from diazoesters, the sulfonylazide 22 may
react with the ferrous state of the P450 via loss of dinitrogen to
yield the iron nitrenoid 23 (Scheme 11A). Intramolecular
insertion of the nitrenoid into one of the substrate’s benzylic
C−H bonds then generates the benzosultam 24, while
returning the cofactor to the ferrous state. Whereas wild-type
P450BM3 displayed low activity toward this transformation
(TTN = 2), variants incorporating both the C400S and T268A
mutations were much more eﬃcient amination catalysts (120
TTN performed by P411BM3 T268A in vitro). P411BM3-CIS
T438S, which incorporates both of these mutations, was an
Scheme 9. Cyclopropanation by Heme-Containing Proteins
Having Axial Histidine Ligation46,a
aThe active site architecture of myoglobin was used by Fasan and co-
workers to identify mutations at H64 and V68 that greatly enhance
styrene cyclopropanation activity.50 The heme is shown in gray, active
site residues are in yellow, and iron is in orange; PDB: 1A6K.51
Scheme 10. N−H and S−H Insertion Reactions Catalyzed by
Heme-Dependent Proteins52−54
Scheme 11. Cytochrome P450s Catalyze C−H Amination
Reactions via Nitrene Transfer48,56,59
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even better catalyst, aﬀording sultam 24 in 58% yield and 87%
ee with 430 total turnovers.
Fasan has demonstrated that other P450BM3 variants,
interestingly lacking either the C400S or T268A mutation,
can also catalyze the C−H amination of sulfonylazides with up
to 388 total turnovers.57 Thus, a particular axial ligand is not
strictly required to achieve hundreds of turnovers, and other
mutations can generate the same (moderate) level of
performance. Fasan has shown that Mb variants are also
capable of performing the intramolecular C−H amination of
sulfonylazides (with up to 200 turnovers)58 and has
demonstrated that azidoformates can function as nitrenoid
precursors in P450-catalyzed C−H amination, providing access
to oxazolidinone products (Scheme 11B).59
Whereas small-molecule metal complexes also enable
enantioselective C−H amination, the regioselectivity of
insertion is commonly dictated by the nature of the
substrate.41,42 In contrast, this laboratory recently demonstrated
that the P450 active site can be engineered to promote
regiodivergent outcomes in C−H amination.48 The sulfonyla-
zide substrate 25 features two potential sites for C−H
insertion: amination at the benzylic (α) position leads to the
ﬁve-membered sultam 26, whereas amination at the homo-
benzylic (β) position leads to the six-membered sultam 27
(Scheme 11C). Although the C−H bonds at the β position are
signiﬁcantly stronger (BDE = ∼98 kcal/mol vs ∼85 kcal/mol at
α), variant P411BM3-CIS T438S I263F strongly favors C−H
insertion at this site (97:3 27/26), demonstrating the ability of
the protein sequence to override the inherent reactivity of the
cofactor and control reaction outcomes. P411BM3 T268A F87A,
in contrast, preferentially catalyzes insertion at the benzylic
position (70:30 26/27). The demonstration of catalyst-
controlled regioselectivity in an insertion process highlights
the ability of enzymes to address historical challenges for small-
molecule catalysts.
In addition to these intramolecular C−H insertion reactions,
heme-dependent enzymes also catalyze intermolecular nitrene
transfer. Our group has shown that tosyl azide (TsN3) serves as
a suitable reagent for generation of an iron nitrenoid with
various cytochrome P411s. This reactive intermediate may be
intercepted by either sulﬁde or oleﬁn nucleophiles to yield the
products of sulﬁmidation60 or aziridination,61 respectively
(Scheme 12). In the case of the intermolecular aziridination
reaction, targeted mutagenesis and screening were performed
to evolve the parent (P411BM3-CIS T438S I263F, 40% yield,
55% ee in the aziridination of 4-methylstyrene) into a more
active and much more selective nitrene transfer catalyst (55%
yield, 99% ee). Notably, although the hemin cofactor alone
displays some (typically low) activity toward other carbene and
nitrene transfer reactions, it does not catalyze sulﬁmidation or
aziridination. The creation of active P411 catalysts for these
reactions highlights the ability of proteins to confer activity
upon otherwise poorly active catalytic motifs.
Heme-dependent enzymes performing carbene and nitrene
transfers in many cases perform as well as small-molecule
catalysts developed for the same reactions with respect to
turnover numbers. For instance, achieving tens of thousands of
turnovers for cyclopropanation ranks these enzymes among the
most eﬃcient catalysts for enantioselective carbene transfer.62
Transition metal catalysts developed for asymmetric nitrene
transfer are typically capable of fewer than one hundred
turnovers, making the enzymes comparable to the most active
metal complexes that have been reported.63 Enzymes compare
unfavorably to the best small-molecule catalysts, however, on an
activity per weight basis. This is balanced by the fact that
enzymes are prepared simply by growing bacterial cells. Many
of the reactions reported do not even require puriﬁcation of the
enzyme: the whole bacterial cells can be used for the
biotransformation. Compared to small-molecule catalysts, the
enzymes developed to date for this chemistry are active on a
narrow range of substrates, and further engineering will be
required to achieve broader activity proﬁles.
Most signiﬁcantly, the development of chemomimetic
carbene and nitrene transfers by heme-dependent enzymes
illustrates the ability of existing enzymes to perform new
transformations via the reactive intermediates that form when
the biocatalyst is exposed to nonbiological reagents (diazoesters
and azides). As suitable carbenoid and nitrenoid precursors are
absent from the natural world, heme-containing proteins never
had the opportunity to access these reaction manifolds and
evolve these capabilities. This all changes in the laboratory:
although heme proteins initially display, at best, only low levels
of activity toward carbene and nitrene transfers, reaction
eﬃciencies and selectivities are greatly improved by protein
engineering and evolution. Altering the axial heme ligand tunes
the nature of the reactive intermediate itself; that some heme
proteins are remarkably tolerant of mutation at the axial ligand
provides opportunities for new catalyst development.49 Most
other beneﬁcial mutations that have been identiﬁed in P450s or
Mb lie on the distal face of the heme, where they likely
contribute to the binding and productive orientation of
substrates, a hallmark of enzymatic catalysis.
Moreover, once an enzyme is identiﬁed for a given catalytic
activation mode, synthetic chemistry precedent provides a
range of diﬀerent reactions that may be possible. Engineering
an enzyme for improved activity toward a particular non-natural
reaction often enhances its ability to execute other new
reactions within that catalytic manifold, enabling protein
engineers to evolve enzymes toward progressively more and
more challenging reactions. In the context of carbene and
nitrene transfer chemistries, cytochrome P450s seem to lie at
the base of ﬁtness peaks for these new functions, which are
readily scaled by directed evolution. It will be interesting to see
whether the smaller heme proteins such as Mb have similar
inherent capacity for evolutionary tuning of selectivity and
activity.
Scheme 12. Intermolecular Nitrene Transfer in
Sulﬁmidation and Aziridination Reactions60,61
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■ AMINE CATALYSIS
Enzymes may also catalyze nonbiological reactions using
amines present in proteinogenic amino acids; although they
are not cofactors, amino groups can be exploited to perform
new reaction types just as thiamine and heme functionalities
have been exploited in the studies described above. Amino-
catalysis, the use of small-molecule amines to catalyze
transformations of carbonyl compounds, has emerged relatively
recently as a powerful method for asymmetric bond
construction. Most commonly, these catalysts achieve substrate
activation via the generation of either enamine or iminium ion
intermediates. In enamine catalysis, condensation of an
aldehyde or ketone substrate with the secondary amine catalyst
followed by tautomerization yields an enamine intermediate
(28), rendering the carbonyl α-position nucleophilic and
facilitating reaction with a range of electrophiles (E+) (Scheme
13A).64 This enamine mechanism is also utilized in nature: type
I adolases employ the ε-amino group of lysine as a nucleophilic
amine catalyst to achieve aldol couplings.65
Alternatively, in iminium catalysis, condensation of the amine
with an α,β-unsaturated carbonyl compound provides an α,β-
unsaturated iminium ion (29) in which the β-carbon is
activated toward coupling with nucleophiles (Nuc−) (Scheme
13B).66 No biological examples of this β-activation strategy are
known. Notably, the simple amino acid proline is a versatile
organocatalyst, and the discoveries in 2000 that proline and its
derivatives catalyze enantioselective aldol reactions (via an
enamine mechanism)67 as well as enantioselective Diels−Alder
reactions (via an iminium mechanism)68 initiated a period of
intense research in aminocatalysis. These two activation modes
have been exploited to achieve a large number of reactions that
have no known biological equivalents, prompting researchers to
examine amine-containing proteins as catalysts for these
reaction types.
The homohexameric enzyme 4-oxalocrotonate tautomerase
(4-OT) features a catalytic amino-terminal proline located in an
active site where it has a pKb ≈ 6.4.69 In the natural function of
4-OT, this residue (Pro1) acts as a general base to promote the
conversion of 2-hydroxy-2,4-hexadienedioate (30) into 2-oxo-
3-hexendioate (31) (Scheme 14A). Seeking to mimic the
structures and activities of proline-based organocatalysts,
Poelarends and co-workers hypothesized that this residue
might be capable of functioning as a nucleophilic catalyst to
carry out enamine-mediated transformations. By exposing the
enzyme to the appropriate reagents, they demonstrated that 4-
OT can catalyze a non-natural Michael-type addition of
aldehydes to nitroalkenes (Scheme 14B).70 Evidence for
enamine formation at Pro1 was provided by mutagenesis and
covalent modiﬁcation studies as well as crystallography.71 Thus,
a change in substrate is suﬃcient to alter the function of the N-
terminal proline from acting as a general base catalyst to acting
as a nucleophilic catalyst. 4-OT catalyzes the α-coupling of a
range of alkyl aldehydes with diverse nitroalkene acceptors,
often providing the product γ-nitroaldehydes with good to
excellent enantioselectivity; the reaction may also be carried out
in whole cells.72 As proline residues at any position other than
the N-terminus lack the ability to form enamine intermediates,
Pro1 is cofactor-like in the sense that it is not widespread in
proteins and must, in fact, be installed via a post-translational
modiﬁcation of the N-terminus.
Enamine-mediated Michael reactions have also been carried
out using the catalytic antibody 38C2; this antibody was
originally developed to catalyze aldol reactions via the ε-amino
group of an active-site lysine residue in the manner of type I
aldolases.73 Weinstain et al. demonstrated that 38C2 is also
capable of promoting asymmetric, intramolecular alkylation
reactions via the Michael addition of an enamine intermediate
32 to a pendent enone (Scheme 15).74 The reactions proceed
with high enantioselectivity as well as good diastereoselectivity
for the cis-cyclopentane product.
As noted above, iminium catalysis activates α,β-unsaturated
carbonyl substrates toward the 1,4-conjugate addition of
nucleophiles. In contrast, nature opts to activate electrophiles
for conjugate addition via hydrogen bonding, as in the
mechanism of enoyl-CoA hydratase,75 or via pyridoxal
phosphate (PLP)-dependent generation of α-aminoacrylate
Scheme 13. Enamine (A) and Iminium (B) Activation
Modes of Aminocatalysis64,66,a
aE is a generic electrophile, and Nuc is a generic nucleophile.
Scheme 14. 4-Oxalocrotonate (4-OT) Performs Enamine
Catalysis via an N-Terminal Proline69−71
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intermediates, as in the mechanism of tryptophan and cysteine
synthases.76 By analogy to small-molecule iminium catalysis,
Hilvert and co-workers speculated that a computationally
designed retro-aldolase containing a catalytic lysine residue
could activate enones toward conjugate additions.77 In earlier
studies, artiﬁcial retro-aldolases were designed in silico to
catalyze the degradation of (S)-methodol (33) via condensa-
tion of an active site lysine with the ketone functionality;
formation of iminium 34 precipitates retro-aldol bond cleavage
to give acetone and naphthaldehyde 35 (Scheme 16).78 One of
the experimentally active designs was subsequently optimized
via directed evolution, delivering an improved retro-aldolase
termed RA95.5-8.79 To determine whether this enzyme could
also catalyze 1,4-conjugate addition reactions via formation of
an activated α,β-unsaturated iminium ion such as 36, a variety
of enone and nucleophilic reagents was surveyed. RA95.5-8, in
fact, catalyzes the Michael addition of ethyl 2-cyanoacetate to
enone 37, furnishing the product β-alkyl ketone 38 in high
yield and enantioselectivity (Scheme 16). The Michael activity
of RA95.5-8 could be improved by evolution, with the
incorporation of two mutations (T53L and K210H) providing
a roughly 3-fold rate enhancement.
The examples of enamine and iminium catalyses discussed
here demonstrate that enzymes are capable of performing
unnatural aminocatalytic reactions. As in the carbene and
nitrene transfer activities developed with heme-dependent
enzymes, these functions were inspired by the activities of
small-molecule catalysts and then achieved by combining
appropriate enzymes with the required chemical reagents
(aldehydes, nitroalkenes, or enones). In the three studies
described, the parent enzyme (4-OT, 38C2, or RA95.5-8) was
selected based on the knowledge that it performs catalysis using
its amine functionality. Notably, the parent could be a natural
enzyme, a catalytic antibody, or a computationally designed
catalyst.
One drawback to catalysis by small-molecule amines is a
need for high catalyst loadings; examples of either enamine or
iminium catalysis proceeding with greater than 100 turnovers
are rare.80 In this context, Hilvert’s development of an enzyme
for iminium catalysis capable of greater than 700 turnovers is a
notable accomplishment. Given the much greater molecular
weight of enzymes compared to the simple architectures of
many small-molecule organocatalysts, however, even greater
eﬃciencies will be required for these enzymes to be competitive
for synthetic purposes. Taking inspiration from these studies,
other non-natural amine-catalyzed reactions will likely be
accessible to enzymes, and further eﬀorts may yield enzyme
catalysts that exceed the capabilities of small molecules with
regard to either activity or eﬃciency.
■ ARTIFICIAL COFACTORS
The availability of enzymes containing thiazolium, metal-
loporphyrin, and amine functionalities has enabled the
introduction of functions ﬁrst established with synthetic
catalysts into biocatalysis. For many reaction classes accessible
to synthetic catalysts, however, no obvious candidates exist in
the enzyme world that may readily take on those functions.
This activity gap has inspired chemists to introduce artiﬁcial
cofactors into protein scaﬀolds, with the aim that a particular
new functional group or metal will allow a desired reaction to
take place, while the presence of a protein scaﬀold will enable
control of the reaction pathway in ways not possible with small
molecules.81 By far, the majority of artiﬁcial cofactors that have
been introduced into proteins are metal ions or metal
complexes; when they are catalytically active, the resulting
complexes are known as artiﬁcial metalloenzymes. Many of the
artiﬁcial metalloenzymes that have been developed perform
reactions that are catalyzed by existing enzymes;82 in some
cases, however, the installation of a metal has enabled functions
that are absent in nature.
In the cofactor-dependent enzymes discussed above, highly
speciﬁc interactions and recognition motifs have evolved to
bind the cofactor to its cognate protein. In contrast, catalysis
with an artiﬁcial cofactor (and, particularly, enantioselective
catalysis) usually requires the installation of the cofactor at a
speciﬁc site in a scaﬀold that has not evolved to bind it. One
general strategy for the site-speciﬁc introduction of an artiﬁcial
metal cofactor in a protein makes use of the extremely high
aﬃnity of the organic cofactor biotin for the proteins avidin and
streptavidin (Ka = ∼1014 M−1). In a seminal report, Whitesides
described the synthesis of the rhodium complex 39, in which
the metal center is tethered to the carboxylate side chain of
biotin via a diphosphine motif (Scheme 17).83 Modiﬁcation of
biotin with the metal complex does not impede binding to
avidin, and simply combining these components generates a
noncovalent artiﬁcial metalloenzyme adduct; this complex
performs the hydrogenation of α-acetamidoacrylic acid (40)
with moderate enantioselectivity (41% ee). Thus, binding of
Scheme 15. Intramolecular Michael Addition Catalyzed by
the Catalytic Antibody 38C2 via an Enamine Mechanism74
Scheme 16. Enzymatic Asymmetric Michael Addition via
Iminium Catalysis Performed by the Retro-Aldolase RA95.5-
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the modiﬁed biotin cofactor to avidin positions the achiral
rhodium center in a chiral pocket that is capable of
accommodating substrates as well as inducing asymmetry
during catalysis.
Ward and co-workers have extensively investigated the
applications of this metallobiotin concept.84 First, Ward
demonstrated that the metalloenzyme derived from streptavidin
(Sav, which features a deeper biotin-binding pocket than
avidin) is a more selective hydrogenation catalyst than the
corresponding avidin complex.85 In particular, the variant Sav
S122G hydrogenates amidoacrylate 40 with excellent enantio-
selectivity (96% ee). Using diﬀerent transition metals and
ligand scaﬀolds, the biotin−(strept)avidin system has been
further employed to achieve the transfer hydrogenation of
ketones86 and imines,87 a palladium-catalyzed asymmetric
allylic alkylation,88 and an asymmetric rhodium-catalyzed C−
H insertion/benzannulation reaction (Scheme 17).89 Optimi-
zation of these transformations was performed via both
alteration of the transition metal/biotin complex and genetic
manipulation of the (strept)avidin scaﬀold.
Directed evolution of the biotin−(strept)avidin system has
been performed by Reetz, but these eﬀorts were constrained by
the requirement for protein puriﬁcation prior to catalysis.90
Ward and co-workers, therefore, developed a protocol for
extraction of (strept)avidin from crude cell extracts by
immobilization on biotinylated Sepharose; as avidin and
streptavidin are homotetrameric, one subunit may bind to the
solid support while leaving other subunits available for
catalysis.91 This protocol was used to screen moderately sized
libraries, delivering streptavidin variants capable of performing
the transfer hydrogenation of ketones with excellent
selectivities (up to 96% ee).
In related work, Ward and co-workers have shown human
carbonic anhydrase II to be a useful platform for metalloenzyme
creation based on the high aﬃnity of its zinc cofactor for aryl
sulfonamide ligands; as in the biotin chemistry described above,
the sulfonamide ligand may be linked to a metal complex.93 In
the case of one construct, computational design was employed
to improve the binding of the artiﬁcial cofactor to the protein,
resulting in an assembly with 4-fold improved activity for the
transfer hydrogenation of imines.94
In contrast to the reactions above, which proceed via
organometallic intermediates, metal ions may also act as Lewis
acids. Roelfes and co-workers constructed enzymes for this
mode of catalysis by covalently conjugating deﬁned metal-
binding sites, namely, a 2,2′-bipyridine or phenanthroline
moiety, to cysteine residues introduced into the dimeric
transcription factor LmrR (Lactococcal multidrug resistance
regulator) from Lactococcus lactis.95 This scaﬀold possesses a
large hydrophobic pore at the interface between LmrR
monomers, and the sites for cysteine conjugation were selected
such that two metal-binding ligands might project into this
dimer interface, one on each monomer. Conjugation followed
by puriﬁcation and treatment with a copper(II) salt then
generated artiﬁcial metalloenzymes capable of functioning as
Lewis acid catalysts; these constructs promote asymmetric
Diels−Alder95 and hydration reactions.96
Metal-binding sites may also be incorporated into proteins by
genetically encoding noncanonical amino acids; for example,
Schultz and co-workers achieved genetic incorporation of (2,2′-
bipyridin-5-yl)alanine (BpyAla) via amber stop codon
suppression.97 Using this methodology, Roelfes introduced
BpyAla into LmrR, thereby eliminating the need to perform a
separate conjugation step to assemble the active catalyst
(Scheme 18).98,99 Installing the unnatural amino acid again at
the dimer interface and using copper(II) as the metal ion
generated artiﬁcial metalloenzymes that catalyze the enantio-
selective Friedel−Crafts alkylation of indoles (Scheme 18).
Selective catalysis required optimization of the site of unnatural
amino acid incorporation (incorporation at M89 was found to
give the best performance) as well as the introduction of an
Scheme 17. Artiﬁcial Metalloenzymes Based on Binding of
Biotin-Tethered Metal Complexes to
(Strept)Avidin83,85,88,89,a
aSav = streptavidin; PDB: 1STP.92
Scheme 18. Friedel−Crafts Alkylation Enabled by Genetic
Incorporation of a Metal-Binding Motif98,a
aLmrR is the Lactococcal multidrug resistance regulator; the two
monomers are shown in blue and yellow and M89 is shown in red in
the wild-type structure; PDB: 3F8B.102
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additional mutation (F93W) in the vicinity of the new catalytic
center.
Notably, covalent attachment of the ligand is not actually
required in this system: Roelfes also demonstrated that a
phenanthroline−copper(II) complex binds noncovalently at
the LmrR dimer interface, providing an artiﬁcial metalloenyzme
competent at performing the Friedel−Crafts alkylation.100
Reetz also demonstrated that noncovalent association between
a phthalocyanine−copper complex and bovine serum albumin
(BSA) is suﬃcient for enantioselective catalysis of Diels−Alder
reactions.101
Lewis has also developed an approach to artiﬁcial metal-
loenzyme assembly based on unnatural amino acid (UAA)
incorporation. Instead of binding the metal directly, however,
the UAA contains an azide that undergoes strain-promoted
azide−alkyne cycloaddition with a bicyclononyne-substituted
metal complex.103 The bioorthogonal azide−alkyne coupling
reaction ensures speciﬁcity for conjugation of the metal
complex at a desired site and avoids cross-reactivity with
protein side chains or the components of cell lysate. In an
application of this strategy, Lewis and co-workers incorporated
a dirhodium tetracarboxylate complex into prolyl oligopepti-
dase (POP), a protease with a large internal cavity.104 A single
unnatural amino acid, L-4-azidophenylalanine, was incorporated
in the interior of the protein in place of the protease’s catalytic
cysteine residue, and subsequent cycloaddition with bicyclono-
nyne 41 delivered the covalent enzyme−dirhodium complex
(Scheme 19). Notably, achieving conjugation required
mutating four large residues on one face of the protein to
alanine, thereby enlarging a pore and presumably allowing the
large cofactor 41 to access the site of UAA incorporation. The
resulting enzyme catalyzes the cyclopropanation of styrenes
with donor−acceptor diazo compounds via a rhodium
carbenoid, providing cyclopropanes such as 42. Three further
beneﬁcial mutations were identiﬁed in the active site, providing
a construct capable of performing cyclopropanation with good
yields and high enantioselectivities as well as reducing the
extent of a side reaction: carbenoid degradation via formal
insertion into the O−H bond of water.
Work in the artiﬁcial metalloenzyme ﬁeld has demonstrated
that nonbiological reactive centers (including many metals that
are rare or absent in biology, such as rhodium) can be
introduced into proteins that have not evolved for any explicit
metal-binding capability. These constructs have been shown to
be selective catalysts for a number of synthetically useful
transformations, validating their designs based on the mimicry
of known chemical catalysts. The logic of chemomimetic
biocatalysis is thus applicable to both naturally cofactor-
dependent enzymes and artiﬁcial cofactor-containing con-
structs. However, the eﬃciency of these metalloenzymes is
typically poor; many of the systems described above are not
capable of more than 100 turnovers (although, in select cases,
thousands of turnovers have been reported87). Most artiﬁcial
metalloenzymes are thus not as eﬃcient as the best small-
molecule catalysts for the same reactions.62,105 Furthermore,
many of these systems are not amenable to directed evolution,
typically because they require puriﬁcation and catalyst
assembly, because catalysis is not compatible with the
components of cell lysate, or because the starting activities
are simply too low for screening to ﬁnd beneﬁcial mutations.
Developing systems that are amenable to high-throughput
genetic optimization is a challenge to which the ﬁeld is now
responding in order to create exceptional catalysts.
■ CONCLUSIONS
We have described an approach to creating novel enzyme
activity based on exploiting functionalities naturally present in
enzymes for new purposes. As there is signiﬁcant overlap
between the properties of certain enzyme cofactors and small-
molecule catalysts, synthetic chemistry can serve as an
inspiration and blueprint for reaction pathways that can be
introduced into biocatalysis (what we have termed a chemo-
mimetic approach to biocatalysis). Thus, new activities may be
discovered in or introduced into existing enzymes by exploiting
the catalytic potential of their heme, thiamine, amine, and other
functional groups. In addition, proteins can be augmented with
artiﬁcial metal cofactors to perform non-natural metal-catalyzed
transformations. Again, these processes draw inspiration from
synthetic reactions and seek to mimic, in a protein environ-
ment, processes that were ﬁrst established with small molecules.
It is interesting to note that protein engineers and synthetic
chemists may ﬁnd somewhat diﬀerent solutions to the same
problems; for instance, whereas rhodium complexes are
generally the most versatile small-molecule catalysts for carbene
and nitrene transfers, the examples discussed here show that
iron-containing enzymes can, in some cases, perform
comparably. Likewise, protein engineers have taken advantage
of the natural cofactor thiamine to perform acyl anion
chemistry, whereas chemists have found that triazolium
catalysts are preferable for many applications. Thus, the optimal
small-molecule and enzymatic catalysts for a given reaction
might be structurally similar, but key features of the catalyst,
such as the identity of the metal, need not be the same. These
diﬀerences arise in part because proteins are especially good at
modulating and contributing to the reactivity of their cofactors,
creating a structural ensemble at the active site with properties
distinct from those of either protein or cofactor alone. We
anticipate that these advantages can also be exploited by
metalloenzymes made from artiﬁcial cofactors.
Although protein engineers have exploited several classes of
cofactor-dependent enzymes for creating new activities, the
natural diversity of cofactor-dependent enzymes oﬀers many
Scheme 19. Artiﬁcial Dirhodium Metalloenzyme
Constructed from Prolyl Oligopeptidase (POP) Catalyzes
Enantioselective Styrene Cyclopropanation104
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further opportunities. Pyridoxal phosphate (PLP)-dependent
enzymes,106 for instance, have been targets of extensive protein
engineering, but, to date, these eﬀorts have largely focused on
native-like reactivity. Other cofactor-dependent enzymes, such
as those that utilize the 4-methylideneimidazole-5-one
(MIO),107 adenosylcobalamin,108 and S-adenosyl methionine
(SAM) cofactors,109 promote remarkable synthetic trans-
formations in nature but have not been widely explored for
biocatalytic applications distant from their native chemistries.
Given the unique mechanistic pathways enabled by these
cofactors, these enzymes are promising candidates for
introducing further new functions.
For many of the non-natural reactions that have been
reported, the enzyme catalysts do not (yet) outperform small
molecules in terms of total turnovers, reaction rates, or
enantioselectivities. Creating useful enzymes will thus depend
on directed evolution, for which cofactor-dependent enzymes
should be well-suited. Although natural cofactors are often
structurally complex molecules, they are supplied directly by
metabolism and thus do not require independent preparation
by chemical synthesis. Furthermore, their assembly into the
enzyme is preprogrammed by the protein and the host cell,
eliminating any need for protein puriﬁcation and laborious
catalyst assembly. Facile catalyst assembly and activity in
complex environments is useful for the implementation of the
high-throughput screening protocols often required for directed
evolution.
We have discussed several examples in which the non-natural
activities of thiamine-, heme-, and amine-dependent enzymes
have been enhanced by directed evolution. In some cases, new
activities could be improved via semirational approaches such
as mutagenesis of key catalytic residues. In the majority of
cases, however, extensive evolution has not been performed,
either due to a lack of eﬀective screening protocols or, as is
typically the case for artiﬁcial metalloenzymes, the requirement
for puriﬁcation and/or in vitro assembly of the catalyst. Given
that supporting entirely new mechanisms of catalysis likely
requires signiﬁcant structural reorganization of enzymes’ active
sites as well as tuning of global enzyme properties, we expect
that the eﬃciencies reported in the literature for these systems
are far removed from the capabilities that can be accessed by
changes to the protein sequence. Evolution will also likely
enable protein engineers to pursue more and more diﬃcult
reactions, as mutations that are generally activating toward a
given non-natural catalytic manifold (such as nitrene transfer or
iminium catalysis) are identiﬁed. We anticipate that it will be
possible to evolve enzymes to perform non-natural reactions
with high levels of eﬃciency and selectivity and even the ability
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(6) (a) Röthlisberger, D.; Khersonsky, O.; Wollacott, A. M.; Jiang, L.;
DeChancie, J.; Betker, J.; Gallaher, J. L.; Althoff, E. A.; Zanghellini, A.;
Dym, O.; Albeck, S.; Houk, K. N.; Tawfik, D. S.; Baker, D. Nature
2008, 453, 190. (b) Siegel, J. B.; Zanghellini, A.; Lovick, H. M.; Kiss,
G.; Lambert, A. R.; St. Clair, J. L.; Gallaher, J. L.; Hilvert, D.; Gelb, M.
H.; Stoddard, B. L.; Houk, K. N.; Michael, F. E.; Baker, D. Science
2010, 329, 309. (c) Khare, S. D.; Kipnis, Y.; Greisen, P. J.; Takeuchi,
R.; Ashani, Y.; Goldsmith, M.; Song, Y.; Gallaher, J. L.; Silman, I.;
Leader, H.; Sussman, J. L.; Stoddard, B. L.; Tawfik, D. S.; Baker, D.
Nat. Chem. Biol. 2012, 8, 294. (d) Hilvert, D. Annu. Rev. Biochem.
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